IS7809A - Pýridínafleiður sem CB2 viðtakastillar - Google Patents
Pýridínafleiður sem CB2 viðtakastillarInfo
- Publication number
- IS7809A IS7809A IS7809A IS7809A IS7809A IS 7809 A IS7809 A IS 7809A IS 7809 A IS7809 A IS 7809A IS 7809 A IS7809 A IS 7809A IS 7809 A IS7809 A IS 7809A
- Authority
- IS
- Iceland
- Prior art keywords
- pyridine derivatives
- receptor regulators
- regulators
- receptor
- pyridine
- Prior art date
Links
- 102000009135 CB2 Cannabinoid Receptor Human genes 0.000 title 1
- 108010073376 CB2 Cannabinoid Receptor Proteins 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0222493.9A GB0222493D0 (en) | 2002-09-27 | 2002-09-27 | Compounds |
| PCT/EP2003/010930 WO2004029026A1 (en) | 2002-09-27 | 2003-09-25 | Pyridine derivatives as cb2 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7809A true IS7809A (is) | 2005-04-19 |
Family
ID=9944904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7809A IS7809A (is) | 2002-09-27 | 2005-04-19 | Pýridínafleiður sem CB2 viðtakastillar |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20060240048A1 (is) |
| EP (1) | EP1565442B1 (is) |
| JP (1) | JP2006503845A (is) |
| KR (1) | KR20050071514A (is) |
| CN (1) | CN1703402A (is) |
| AR (1) | AR041395A1 (is) |
| AT (1) | ATE378317T1 (is) |
| AU (1) | AU2003268907A1 (is) |
| BR (1) | BR0314635A (is) |
| CA (1) | CA2500231A1 (is) |
| DE (1) | DE60317555T2 (is) |
| ES (1) | ES2294313T3 (is) |
| GB (1) | GB0222493D0 (is) |
| IS (1) | IS7809A (is) |
| MA (1) | MA27448A1 (is) |
| MX (1) | MXPA05003263A (is) |
| NO (1) | NO20052028L (is) |
| NZ (1) | NZ538943A (is) |
| PL (1) | PL375990A1 (is) |
| RU (1) | RU2005112752A (is) |
| TW (1) | TW200413321A (is) |
| WO (1) | WO2004029026A1 (is) |
| ZA (1) | ZA200502084B (is) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2479744A1 (en) | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
| UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| GB0402355D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402356D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| GB0402357D0 (en) * | 2004-02-03 | 2004-03-10 | Glaxo Group Ltd | Novel compounds |
| SE0401343D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine N oxide as scaffold |
| SE0401345D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds: Pyridine as scaffold |
| SE0401342D0 (sv) * | 2004-05-25 | 2004-05-25 | Astrazeneca Ab | Therapeutic compounds |
| JP2008501758A (ja) | 2004-06-09 | 2008-01-24 | グラクソ グループ リミテッド | ピロロピリジン誘導体 |
| EA200800562A1 (ru) * | 2005-08-09 | 2008-06-30 | Глаксо Груп Лимитед | Производные имидазопиридина в качестве лигандов каннабиноидного рецептора |
| GB0519760D0 (en) * | 2005-09-28 | 2005-11-09 | Glaxo Group Ltd | Novel compounds |
| CA2643863A1 (en) * | 2006-04-07 | 2007-10-18 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
| JP5064506B2 (ja) | 2006-10-04 | 2012-10-31 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｂ２受容体調節因子としてのピラジン−２−カルボキサミド誘導体 |
| WO2008063625A2 (en) * | 2006-11-20 | 2008-05-29 | Adolor Corporation | Pyridine compounds and methods of their use |
| CN101687117B (zh) * | 2007-02-22 | 2013-06-26 | 汉默卢斯医药有限责任公司 | 高容量生物流体过滤设备 |
| KR20110117146A (ko) * | 2009-01-22 | 2011-10-26 | 라퀄리아 파마 인코포레이티드 | Ｃｂ2 수용체 효능활성이 있는 ｎ-치환 포화 헤테로사이클릭 술폰 화합물 |
| RU2011143740A (ru) | 2009-03-30 | 2013-05-10 | Астеллас Фарма Инк. | Соединение пиримидина |
| JP5727482B2 (ja) * | 2009-08-24 | 2015-06-03 | ニューラルステム， インコーポレイテッド | 神経刺激性ピペラジンの合成 |
| US9321727B2 (en) | 2011-06-10 | 2016-04-26 | Hoffmann-La Roche Inc. | Pyridine derivatives as agonists of the CB2 receptor |
| JP2013048962A (ja) * | 2012-12-12 | 2013-03-14 | Hemerus Medical Llc | 大容量の体液濾過装置 |
| WO2018055640A1 (en) * | 2016-09-22 | 2018-03-29 | Srf Limited | Process for the preparation of haloalkyl derivatives of nicotinic acid |
| MA53002A (fr) * | 2018-06-27 | 2021-05-05 | Eth Zuerich | Nouveaux composés de pyridine et de pyrazine en tant qu'inhibiteurs du récepteur cannabinoïde 2 |
| EP3813888B1 (en) | 2018-06-27 | 2025-11-26 | F. Hoffmann-La Roche AG | Radiolabeled cannabinoid receptor 2 ligand |
| WO2020002280A1 (en) | 2018-06-27 | 2020-01-02 | F. Hoffmann-La Roche Ag | Novel azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 |
| WO2020025574A1 (en) | 2018-08-03 | 2020-02-06 | Bayer Aktiengesellschaft | Process for the preparation of 6-(haloalkyl)-2-halo-5-acylpyridines and intermediates for this process |
| EP3666759A1 (en) | 2018-12-10 | 2020-06-17 | Bayer Aktiengesellschaft | Preparation of 6-halo-2-(haloalkyl)-3-acylpyridines and intermediates therefor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5112820A (en) * | 1990-03-05 | 1992-05-12 | Sterling Drug Inc. | Anti-glaucoma compositions containing 2- and 3-aminomethyl-6-arylcarbonyl- or 6-phenylthio-2,3-dihydropyrrolo-(1,2,3-de)-1,4-benzoxazines and method of use thereof |
| FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6022884A (en) * | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| US7507767B2 (en) * | 2001-02-08 | 2009-03-24 | Schering Corporation | Cannabinoid receptor ligands |
-
2002
- 2002-09-27 GB GBGB0222493.9A patent/GB0222493D0/en not_active Ceased
-
2003
- 2003-09-25 WO PCT/EP2003/010930 patent/WO2004029026A1/en not_active Ceased
- 2003-09-25 MX MXPA05003263A patent/MXPA05003263A/es unknown
- 2003-09-25 DE DE60317555T patent/DE60317555T2/de not_active Expired - Fee Related
- 2003-09-25 AU AU2003268907A patent/AU2003268907A1/en not_active Abandoned
- 2003-09-25 AT AT03750676T patent/ATE378317T1/de not_active IP Right Cessation
- 2003-09-25 EP EP03750676A patent/EP1565442B1/en not_active Expired - Lifetime
- 2003-09-25 RU RU2005112752/04A patent/RU2005112752A/ru not_active Application Discontinuation
- 2003-09-25 JP JP2004539056A patent/JP2006503845A/ja not_active Withdrawn
- 2003-09-25 BR BR0314635-9A patent/BR0314635A/pt not_active IP Right Cessation
- 2003-09-25 PL PL03375990A patent/PL375990A1/xx not_active Application Discontinuation
- 2003-09-25 AR ARP030103499A patent/AR041395A1/es not_active Application Discontinuation
- 2003-09-25 US US10/528,613 patent/US20060240048A1/en not_active Abandoned
- 2003-09-25 TW TW092126422A patent/TW200413321A/zh unknown
- 2003-09-25 KR KR1020057005234A patent/KR20050071514A/ko not_active Withdrawn
- 2003-09-25 CN CNA038254727A patent/CN1703402A/zh active Pending
- 2003-09-25 CA CA002500231A patent/CA2500231A1/en not_active Abandoned
- 2003-09-25 NZ NZ538943A patent/NZ538943A/en unknown
- 2003-09-25 ES ES03750676T patent/ES2294313T3/es not_active Expired - Lifetime
-
2005
- 2005-03-11 ZA ZA200502084A patent/ZA200502084B/en unknown
- 2005-03-28 MA MA28176A patent/MA27448A1/fr unknown
- 2005-04-19 IS IS7809A patent/IS7809A/is unknown
- 2005-04-26 NO NO20052028A patent/NO20052028L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ538943A (en) | 2007-01-26 |
| JP2006503845A (ja) | 2006-02-02 |
| AU2003268907A1 (en) | 2004-04-19 |
| WO2004029026A1 (en) | 2004-04-08 |
| CN1703402A (zh) | 2005-11-30 |
| EP1565442A1 (en) | 2005-08-24 |
| TW200413321A (en) | 2004-08-01 |
| ES2294313T3 (es) | 2008-04-01 |
| NO20052028L (no) | 2005-06-03 |
| EP1565442B1 (en) | 2007-11-14 |
| ZA200502084B (en) | 2006-02-22 |
| ATE378317T1 (de) | 2007-11-15 |
| AR041395A1 (es) | 2005-05-18 |
| PL375990A1 (en) | 2005-12-12 |
| KR20050071514A (ko) | 2005-07-07 |
| RU2005112752A (ru) | 2006-01-20 |
| US20060240048A1 (en) | 2006-10-26 |
| MA27448A1 (fr) | 2005-07-01 |
| DE60317555T2 (de) | 2008-10-23 |
| BR0314635A (pt) | 2005-08-02 |
| CA2500231A1 (en) | 2004-04-08 |
| DE60317555D1 (de) | 2007-12-27 |
| MXPA05003263A (es) | 2005-07-05 |
| GB0222493D0 (en) | 2002-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS8466A (is) | 3-Sýklóalkýlamínópýrrólidín afleiður sem stillar á flakkboða viðtaka | |
| CY2017032I2 (el) | Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2 | |
| ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
| PL375990A1 (en) | Pyridine derivatives as cb2 receptor modulators | |
| IS7945A (is) | 4,5-díarýlþíasólafleiður sem CB-1 tenglar | |
| DE50307455D1 (de) | Einstellsystem | |
| IS7625A (is) | Nýjar samrunnar imídazól afleiður | |
| AP2005003343A0 (en) | Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors | |
| FR14C0045I2 (fr) | Nouveau derive de 2-pyridylethylbenzamide | |
| ATE478870T1 (de) | Spiroindolinpiperidinderivate | |
| DK1556385T3 (da) | Heterocyclocarboxamid-derivater | |
| DK1551802T3 (da) | Indol-3-svovlderivater | |
| ATE438644T1 (de) | Chinazolinderivate | |
| IS7720A (is) | Píperidín-N-oxíð-afleiður | |
| DK1474408T3 (da) | N-Phenyl-2-pyrimidinaminderivater | |
| IL165810A0 (en) | Novel benzimidazole derivatives | |
| DK1361490T3 (da) | Strömningsregulator | |
| DE50302630D1 (de) | Verstellantrieb | |
| ATE335729T1 (de) | 3h-chinazoline -4-on derivaten | |
| DK1636206T3 (da) | Imidazolderivater som glutamatreceptorantagonister | |
| ATE423771T1 (de) | Tetrahydrochinolinderivate | |
| ATE457299T1 (de) | 4-hydroxymethyl-1-aryl-cyclohexylamin-derivativ | |
| DE50306277D1 (de) | 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate | |
| IS7452A (is) | Prógesterón viðtakastillar sem ekki eru steratengdir | |
| IS8278A (is) | Sýkóprópýl afleiður sem NK3 viðtaka mótlyf |